Peer-influenced content. Sources you trust. No registration required. This is HCN.
British Medical Journal (The BMJ)
“Selecting a GLP-1 receptor agonist over another antihyperglycemic drug could plausibly confer ancillary benefit” in patients at high risk for or living with an SUD. — Study authors
Endocrinology, Diabetes, Metabolism March 18th 2026
The Canadian Journal of Psychiatry
“The prevalence of internalizing problems increased more rapidly among Canadians who used cannabis compared to those who do not.” — Study authors
Psychiatry March 18th 2026
Psychiatrist.com
The objective of the study was to characterize the real-world safety profile of TMS devices based on MAUDE-reported AEs, including symptom patterns, manufacturer-level variations, device issues, and reporting delays.
Psychiatry March 4th 2026
Psych Congress Network
“TRD patients have extremely limited treatment options, and the unmet need remains profound.” — Guy Goodwin, MD, CMO, Compass Pathways
“Evenamide has the potential to treat the symptoms of schizophrenia more broadly, addressing also those poorly managed by the currently available antipsychotics.” — Ravi Anand, MD, Therapeutic Advances in Psychopharmacology
Psychiatry February 18th 2026
Cleveland Clinic Journal of Medicine (CCJM)
Deprescribing benzodiazepines in patients on long-term stable treatment led to increased mortality along with increases in nonfatal overdoses, suicidal ideation, and emergency department visits.
Psychiatry January 21st 2026